top of page

ANAVEX New Website - Untitled Page.png

Search

New Exploratory Alzheimer's Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance

Nov 27, 2015

International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) 2015, Barcelona, Spain

Steve Macfarlane, Paul Maruff, Marco Cecchi, Dennis Moore, Tasos Zografidis, Christopher Missling

View Presentation

Recent Posts

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

bottom of page